| Trial | control | p<0.05 | harm | NS |
|---|
| ISTANA (Lee), 2010 | gefitinib vs docetaxel | ORR 3.69 [1.59; 8.58] | | OS 0.87 [0.61; 1.24] PFS 0.73 [0.53; 1.00] |
| V-15-32 (Maruyama), 2008 | gefitinib vs docetaxel | ORR 1.77 [1.18; 2.65] | | OS 1.12 [0.89; 1.40] PFS 0.90 [0.72; 1.12] |
| INTEREST (Kim), 2008 | gefitinib vs docetaxel | | | OS 1.01 [0.90; 1.14] PFS 1.04 [0.92; 1.17] ORR 1.20 [0.84; 1.72] |
| SIGN (Cufer), 2006 | gefitinib vs docetaxel | | | OS 0.97 [0.61; 1.53] PFS 0.94 [0.64; 1.39] ORR 0.97 [0.42; 2.24] |
| IPASS | gefitinib vs carboplatin/paclitaxel | | | |
| West Japan | gefitinib vs | | | |
| Northeast Japan | gefitinib vs | | | |
| First Signal | gefitinib vs gemcitabine and cisplatin | | | |
| Kris, 2003 | gefitinib vs gefitinib | | | |
| INTACT 1. | gefitinib + gemcitabine/cisplatin vs placebo + gemcitabine / cisplatin | | | |
| INTACT 2, 2004 | gefitinib paclitaxel and carboplatin vs paclitaxel and carboplatin | | | |
| CTONG0806 (Yang), 2013 | gefitinib vs | | PFS 1.96 [1.38; 2.79] | |
| NCIC CTG BR19 (Goss), 2013 | gefitinib vs placebo | | | |
| NEJ002, 2013 | gefitinib vs carboplatin-paclitaxel | | | |
| INFORM; C-TONG 0804, 2012 | gefitinib vs placebo | | | |
| EORTC 08021/ILCP 01/03, 2011 | gefitinib vs placebo | | | |
| Maemondo, 2010 | gefitinib vs carboplatin-paclitaxel | | | |
| IFCT-0301 study (Morère), 2010 | gefitinib vs docetaxel | | | |
| WJTOG0203 (Takeda), 2010 | gefitinib vs continued platinum-doublet chemotherapy | | | |
| WJTOG3405 (Mitsudomi), 2010 | gefitinib vs cisplatin plus docetaxel | | | |
| IPASS (Mok), 2009 | gefitinib vs carboplatin-paclitaxel | | | |
| Goss, 2009 | gefitinib vs placebo | | | |
| INVITE (Crinò), 2008 | gefitinib vs vinorelbine | | | |
| SWOG S0023 (Kelly), 2008 | gefitinib vs placebo | | | |
| ISEL, 2006 | gefitinib vs placebo | | | |
| Tsuboi, 2005 | gefitinib vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| ISTANA (Lee), 2010 | (n=-9) vs. (n=-9) | previously treated advanced nonsmall-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| V-15-32 (Maruyama), 2008 | (n=-9) vs. (n=-9) | previously treated advanced nonsmall-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| INTEREST (Kim), 2008 | (n=-9) vs. (n=-9) | previously treated advanced nonsmall-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| SIGN (Cufer), 2006 | (n=-9) vs. (n=-9) | previously treated advanced nonsmall-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| IPASS | (n=-9) vs. (n=-9) | previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma | Sample size: -9/-9 Primary endpoint: FU duration: |
| West Japan | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Northeast Japan | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| First Signal | gefitinib (250 mg daily) (n=159) vs. GP chemotherapy (gemcitabine 1,250 mg/m(2) on days 1 and 8; cisplatin 80 mg/m(2) on day 1 every 3 weeks, for up to nine courses (n=150) | first-line therapy of never-smokers with adenocarcinoma of the lung | Sample size: 159/150 Primary endpoint: FU duration: |
| Kris, 2003 | (n=-9) vs. (n=-9) | Patients either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens | double blind Sample size: -9/-9 Primary endpoint: FU duration: |
| INTACT 1. | gefitinib 500 mg/d, gefitinib 250 mg/d, (n=-9) vs. placebo (n=-9) | chemotherapy-naive patients with unresectable stage III or IV NSCLC | double blind Sample size: -9/-9 Primary endpoint: FU duration: |
| INTACT 2, 2004 | gefitinib plus paclitaxel and carboplatin (n=-9) vs. paclitaxel 225 mg/m(2) and carboplatin area under concentration/time curve of 6 mg/min/mL (day 1 every 3 weeks) (n=-9) | chemotherapy-naive patients with advanced NSCLC | double-blind Sample size: -9/-9 Primary endpoint: FU duration: |
| CTONG0806 (Yang), 2013 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| NCIC CTG BR19 (Goss), 2013 | gefitinib 250 mg per day (n=-9) vs. placebo (n=-9) | completely resected non-small-cell lung cancer | double-blind Sample size: -9/-9 Primary endpoint: FU duration: |
| NEJ002, 2013 | (n=-9) vs. (n=-9) | chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations | Sample size: -9/-9 Primary endpoint: FU duration: |
| INFORM; C-TONG 0804, 2012 | (n=-9) vs. (n=-9) | maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| EORTC 08021/ILCP 01/03, 2011 | (n=-9) vs. (n=-9) | patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy | Sample size: -9/-9 Primary endpoint: FU duration: |
| Maemondo, 2010 | (n=-9) vs. (n=-9) | patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy | Sample size: -9/-9 Primary endpoint: FU duration: |
| IFCT-0301 study (Morère), 2010 | (n=-9) vs. (n=-9) | patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 | Sample size: -9/-9 Primary endpoint: FU duration: |
| WJTOG0203 (Takeda), 2010 | (n=-9) vs. (n=-9) | Japanese patients with advanced non-small-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| WJTOG3405 (Mitsudomi), 2010 | (n=-9) vs. (n=-9) | patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor | Sample size: -9/-9 Primary endpoint: FU duration: |
| IPASS (Mok), 2009 | (n=-9) vs. (n=-9) | previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers | Sample size: -9/-9 Primary endpoint: FU duration: |
| Goss, 2009 | (n=-9) vs. (n=-9) | chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status | Sample size: -9/-9 Primary endpoint: FU duration: |
| INVITE (Crinò), 2008 | (n=-9) vs. (n=-9) | chemotherapy-naive elderly patients with advanced non-small-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| SWOG S0023 (Kelly), 2008 | (n=-9) vs. (n=-9) | inoperable stage III non-small-cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| ISEL, 2006 | (n=-9) vs. (n=-9) | patients of Asian origin with refractory advanced non-small cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| Tsuboi, 2005 | (n=-9) vs. (n=-9) | patients with completely resected non-small cell lung cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
